COVID-19 (Coronavirus) Update

A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA

Protocol No
ECOG-EA3161
Principal Investigator
Aditya Shreenivas
Phase
II/III
Summary
This study is being done to answer the following question: Does maintenance nivolumab following definitive therapy with radiation and chemotherapy (cisplatin) result in significant improvement in overall survival (OS) (time being alive) and progression-free survival (PFS) (time being alive without cancer) for patients with your type of cancer (intermediate risk HPV positive oropharynx cancer). We are doing this study because we want to find out if this approach is better or worse than the usual approach for your HPV positive oropharynx cancer. The usual approach is defined as care most people get for HPV positive oropharynx cancer
Participating Institutions
Froedtert West Bend Hospital
Froedtert Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Share This: